首页> 外文期刊>Journal of Medical Radiation Sciences >Use of 99mTc 2‐methoxyisobutyl isonitrile in minimally invasive radioguided surgery in patients with primary hyperparathyroidism: A narrative review of the current literature
【24h】

Use of 99mTc 2‐methoxyisobutyl isonitrile in minimally invasive radioguided surgery in patients with primary hyperparathyroidism: A narrative review of the current literature

机译:99mTc 2-甲氧基异丁基异腈在原发性甲状旁腺功能亢进症患者微创放射导向手术中的应用:文献综述

获取原文
           

摘要

AbstractThe use of technetium-99m 2-methoxyisobutyl isonitrile (99mTc MIBI) for assistance in minimally invasive radioguided surgery (MIRS) is growing in popularity as a safe, effective, and proficient technique used for parathyroidectomy in primary hyperparathyroidism (PHPT) treatment. Previously, the preferred treatment for PHPT was bilateral neck exploration (BNE), a very invasive, costly, and lengthy procedure. However, as a large majority (80–85% of cases of PHPT) are attributed to a single parathyroid adenoma (PA), a simpler more direct technique such as MIRS is a far better option. The following article is an exploration of the current literature concerning varied protocols utilizing 99mTc MIBI for assistance in MIRS for patients undergoing treatment of PHPT. This technique boasts many advantageous outcomes for patients suffering from PHPT. These include a reduction in cost, operating time, and patient recovery; less evidence of post-surgical hypocalcaemia, less pain, and complications; superior cosmetic results; same-day discharge; and the possibility of local anaesthesia which is particularly beneficial in elderly patients. Better outcomes for patients with deep or ectopic PAs, reduced intra-operative complications, and improved cosmetic outcomes for patients who have previously undergone thyroid and/or parathyroid surgery are also advantageous. Of the literature reviewed it was also found that no patients suffered any major surgical complications such as laryngeal nerve palsy or permanent hypoparathyroidism using 99mTc MIBI for assistance in MIRS.
机译:摘要99m 2-甲氧基异丁基异腈( 99m Tc MIBI)在微创放射导引手术(MIRS)辅助中的应用正日益普及,作为一种安全,有效和精通的原发性甲状旁腺切除术的技术甲状旁腺功能亢进症(PHPT)治疗。以前,PHPT的首选治疗方法是双侧颈部探查(BNE),这是一种侵入性大,成本高且冗长的手术。但是,由于绝大多数(PHPT病例的80–85%)归因于单个甲状旁腺腺瘤(PA),因此,更简单,更直接的技术(如MIRS)是更好的选择。以下文章是有关使用 99m Tc MIBI辅助接受PHPT治疗的MIRS的各种方案的最新文献的探索。对于患有PHPT的患者,这项技术具有许多有利的结果。这些措施包括降低成本,缩短手术时间并减少患者康复;手术后低血钙的证据更少,疼痛和并发症更少;优异的美容效果;当日出院;以及局部麻醉的可能性,这对老年患者特别有益。对于深部或异位PA的患者,更好的结局,术中并发症的减少以及先前接受甲状腺和/或甲状旁腺手术的患者的美容结局也有利。在回顾的文献中还发现,没有患者使用 99m Tc MIBI辅助MIRS进行任何重大手术并发症,例如喉神经麻痹或永久性甲状旁腺功能低下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号